SGAM
HRMY icon

Smith Group Asset Management’s Harmony Biosciences HRMY Stock Holding History

Smith Group Asset Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-400
Closed -$17K – 319
2021
Q4 		$17K Hold
400
– – ﹤0.01% 265
2021
Q3 		$15K Buy
+400
New +$12.9K ﹤0.01% 274

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Smith Group Asset Management's HRMY Position: Q1 2022 in Review

Smith Group Asset Management sold out of Harmony Biosciences (HRMY) in Q1 2022, closing a stake of 400 shares — an estimated $17K sold.

Smith Group Asset Management first reported a position in HRMY in Q3 2021 and held it in 2 quarters. The position peaked at $17K in Q4 2021. 182 funds tracked by Wall St. Rank hold HRMY as of Q1 2022.

  • Smith Group Asset Management reported no remaining Harmony Biosciences position as of Q1 2022 after selling out during the quarter.
  • Smith Group Asset Management sold 400 Harmony Biosciences shares in Q1 2022, an estimated $17K.
  • Smith Group Asset Management first reported a position in Harmony Biosciences in Q3 2021 and held it in 2 quarters.
  • Smith Group Asset Management's Harmony Biosciences position peaked at $17K in Q4 2021.
  • 182 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2022.

Based on Smith Group Asset Management's 13F filing for Q1 2022, filed 5 May 2022.